Guardant Health, Inc. · NASDAQ:GH
Guardant Health — William Blair 42nd Annual Growth Stock Conference 2022
19 slides from Guardant Health's conference presentation, Jun 7, 2022
Slide 1: Transforming cancer care
Transforming cancer care William Blair Growth Conference June 7, 2022
Slide 2: Safe Harbor
Safe Harbor Certain statements in this presentation and the accompanying oral commentary are forward-looking unknown risks and uncertainties, many of which are beyond the Company's control. These and other statements within the meaning of federal securities laws. These statements relate to future ev
Slide 3: Pushing the boundaries of cancer diagnostics and delivering a new paradigm of care
Guardant Health is pushing the boundaries of what is possible in cancer diagnostics and delivering a new paradigm of care Therapy Selection Recurrence Monitoring / MRD Screening 3
Slide 4: Unlocking the market across the continuum of care
Unlocking the across the continuum of care $50B+ $20B+ $10B Screening Recurrence Monitoring Therapy Selection Pre-cancer diagnosis Early-stage cancer Advanced cancer Clinical Diagnosis Surgery Adjuvant Tx Recurrence 1st Line Tx 2nd Line Tx 4 Sources: American Cancer Society Cancer Facts and Statisti
Slide 5: Guardant Health unlocks multiple dimensions of cancer signals in blood
Guardant Health unlocks multiple dimensions of cancer signals in blood Proprietary High- Next-Generation AI-Powered Patient Conversion Biochemistry Sequencing Bioinformatics Report 2-3x 1000x higher conversion reduction in sequencing efficiency error rate 500+ Worldwide Patents and Applications 5 So
Slide 6: Strong record of growth
Cumulative tests ordered Strong record of 275,000+ + 60% CAGR $ 374 M Current ordering oncologists 11,000+ $ 287 M Active biopharma partnerships $ 214 M 110+ $ 91 M Cash, cash equivalents & marketable securities1 2018 2019 2020 2021 $1.6B 6 1. As of 3/31/2022
Slide 7: Unlocking the benefits of scale through a commercial oncology organization
Unlocking the benefits of scale through a 250+ Commercial Oncology Organization 47% YoY Volume Growth #1 Share of Voice Strong growth in BOTH oncologists ordering per Nearly DOUBLE the oncologist interactions quarter AND tests per oncologist in Q1 2022 compare to closest CGP competitor 70% Community
Slide 8: Leading Liquid Biopsy Provider in the Market
Leading Liquid Biopsy Provider in the Market FDA Approval $10B 290+ Publications + 3M tests/year Molecular response & monitoring 200M+ Covered Lives Leading Position in Liquid Biopsy Therapy Selection TAM 8 Market sizing based on Guardant Health internal analysis
Slide 9: Comprehensive Offering
Comprehensive Offering 1 2 3 4 1st Comprehensive Next-Generation 1st Blood-Only Test Next-Generation Liquid Biopsy to Liquid Biopsy Assay to View Molecular Tissue Assay Receive FDA Approval Response 9 9
Slide 10: Establishing the $20B+ recurrence monitoring market
Establishing the $20B+ The FIRST blood-only liquid biopsy for residual >4.5M tests/year disease detection and recurrence monitoring More favorable Reimbursement 7 days Data in early- Plasma only High Initial indication stage CRC, ctDNA test sensitivity1 is CRC, breast, lung, with industry- addition
Slide 11: Strong performance for recurrence monitoring detection
Strong performance for recurrence monitoring detection in Somatic Alterations Methylation SNVs and Indels Differential methylation in including genomic mechanisms of normal vs. tumor DNA therapy resistance (e.g. ESR1) Colorectal Breast2 100 patient cohort, new in 2022 35 patient pilot, new in 2022 H
Slide 12: Patients who are not up to date with screening are at risk
Patients who are not up to date with screening are at 5-YEAR SURVIVAL RATE #2 Cause of cancer deaths 75 % BASED ON STAGE OF DIAGNOSIS2,3 Over of people who died from Early Stage (I-II) 90% CRC were not up to date with screening1 C R C remains the second-leading cause of cancer- Late Stage 14% 1in 3
Slide 13: Preferred screening modality by patients for CRC
screening modality by patients for CRC 64% Blood Based Screening 36% Colonoscopy, FIT or Cologuard 13 Proportion ranking LUNAR-2 as top CRC screening preference*, Overall N=299, GH Internal LUNAR2 Patient Research
Slide 14: Detecting CRC with high accuracy through a simple blood draw
Detecting CRC with high accuracy through a simple blood draw 92% 94% 91% 90% 97% 86% Sensitivity Sensitivity 20% Specificity Specificity Sensitivity Sensitivity AA Detection (Stage I) (Stage II) (Stage III) (Overall) (screen negative) (Overall) Guardant Health’s blood-based approach identifies CRC O
Slide 15: Unlocking a large screening market in 2022 & beyond
Unlocking a in 2022 & beyond Launched ECLIPSE Submit for FDA Approval MCARE Coverage Guidelines Shield LDT Readout FDA Approval & ADLT Status May 2022 2H’ 2022 2H’ 2022 2023 2026 Drives NCD Medicare 3-year interval Drives private payer Reimbursement $500+ pricing reimbursement ~100 700+ Commercial C
Slide 16: Evolving to next generation screening for multi-cancer
Evolving to next generation screening device for Multi-Cancer 90% 90% 87% $50B+ + Average Risk Lung → Multi-cancer + Annual Testing Interval Pancreatic Bladder Lung CRC Liver … $20B Average Risk CRC 3-year testing interval 45 – 84 years old Specificity Sensitivity Sensitivity Screening TAM 16 Sensit
Slide 17: Demonstrated track record of growth
Demonstrated track record of Growth 2022 2022 2020 2021 Y/YRate growth Guidance Guidance22 Tests to Clinical Customers 63.3K 87.6K 38% >50% Tests to Biopharmaceutical Customers 16.0K 18.6K 16% >30% Revenue $287M $374M 30% $460 - $470M Gross Margin 68% 67% Cash & Investments Ending Balance1 $2.0B $1.
Slide 18: Key milestones transforming the continuum of care
Key milestones transforming the continuum of care in Therapy Selection Recurrence Monitoring Screening • TissueNext reimbursement • Demonstrated strong performance • Launched Shield LDT in multi-cancer with Reveal • 2H: ECLIPSE readout • Regulatory approval in Japan • Launch of Multi-cancer Reveal •
Slide 19: Guardant Health
(@) GUARDANT
Guardant Health — William Blair 42nd Annual Growth Stock Conference 2022 on 6ix